Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment
Arch Bronconeumol. 2016 Jan;52(1):36-45.
doi: 10.1016/j.arbres.2015.04.016.
Epub 2015 Jul 14.
[Article in
English,
Spanish]
Authors
Isabel Mir Viladrich
1
, Esteban Daudén Tello
2
, Guillermo Solano-López
2
, Francisco Javier López Longo
3
, Carlos Taxonera Samso
4
, Paquita Sánchez Martínez
5
, Xavier Martínez Lacasa
6
, Mercedes García Gasalla
7
, Jordi Dorca Sargatal
8
, Miguel Arias-Guillén
9
, José Maria García García
10
Affiliations
- 1 Servicio de Neumología, Hospital Son Llàtzer, Palma de Mallorca, España. Electronic address: imir@hsll.es.
- 2 Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España.
- 3 Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
- 4 Servicio Aparato Digestivo, Hospital Clínico San Carlos e Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, España.
- 5 Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, España.
- 6 Unidad control de Tuberculosis, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, España.
- 7 Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Son Llàtzer, Palma de Mallorca, España.
- 8 Servicio de Neumología, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, España.
- 9 Servicio de Neumología, Hospital Universitario Central de Asturias-Instituto Nacional de Silicosis, Oviedo, Asturias, España.
- 10 Servicio de Neumología, Hospital San Agustín, Avilés, Asturias, España.
Abstract
Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy. Screening for the presence of latent infection with Mycobacterium tuberculosis and targeted preventive treatment to reduce the risk of progression to TB is mandatory in these patients. This Consensus Document summarizes the current knowledge and expert opinion of biologic therapies including TNF-blocking treatments. It provides recommendations for the use of interferon-gamma release assays (IGRA) and tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection in these patients, and for the type and duration of preventive therapy.
Keywords:
Biologic therapies; Chronic inflammatory diseases; Enfermedades inflamatorias crónicas; Infección tuberculosa latente; Interferon-gamma release assays; Latent tuberculosis infection; Terapias biológicas; Técnicas de liberación de interferón gamma.
Copyright © 2015 SEPAR. Published by Elsevier Espana. All rights reserved.
Publication types
-
Consensus Development Conference
MeSH terms
-
Biological Therapy*
-
Humans
-
Immunosuppression Therapy
-
Latent Tuberculosis / diagnosis*
-
Latent Tuberculosis / prevention & control
-
Latent Tuberculosis / therapy*
-
Practice Guidelines as Topic